Today The New England Journal of Medicine published the detailed results.

Sunday, February 25, 2024 Antibody Reduces Allergic Reactions to Multiple Foods in NIAID Trial Credit: Adobe Stock An NIAID study published today in The New England Journal of Medicine found a 16-week course of omalizumab increased the amount of peanut, tree nuts, egg, milk and wheat that multi-food allergic children as young as 1 year could eat without an allergic reaction. This Phase 3 clinical trial finding suggests the antibody therapy has the potential to protect children and adolescents if they accidentally eat a food to which they are allergic despite efforts to avoid it. The FDA approved omalizumab (Xolair) for people with food allergy on February 16 based on interim data from the NIAID trial. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107